YES1 Is a Druggable Oncogenic Target in SCLC
Authors:
- 18 August 2022
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 17 (12) , 1387-1403
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Instituto de Salud Carlos III (CB16/12/00390, CB16/12/00442, CB16/12/00443, PI19/00098, PI19/00230)
- European Regional Development Fund
- Merck
- Consejería de Salud y Familias, Junta de Andalucía
- Novartis
- Research Directorate-General (713 406)
- Roche España
- Pfizer
- Ministerio de Educación, Cultura y Deporte
- Merck Sharp and Dohme United Kingdom
- H2020 Marie Skłodowska-Curie Actions
- Bristol-Myers Squibb
- AstraZeneca España
- Eli Lilly and Company
- PharmaMar
- Centro de Investigación Biomédica en Red de Cáncer
- International Association for the Study of Lung Cancer (FPU17/01168)
- Boehringer Ingelheim
This publication has 45 references indexed in Scilit:
- Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP AxisClinical Cancer Research, 2014
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1Cancer Discovery, 2012
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung CancerClinical Cancer Research, 2012
- Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid TumorsJournal of Clinical Oncology, 2012
- Novel strategies for the treatment of small-cell lung carcinomaNature Reviews Clinical Oncology, 2011
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid TumorsJournal of Clinical Oncology, 2011
- The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patientsExpert Opinion on Investigational Drugs, 2011
- Elevated c-Src and c-Yes expression in malignant skin cancersJournal of Experimental & Clinical Cancer Research, 2010
- Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib MesylateClinical Cancer Research, 2008
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004